Fluvoxamine
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Fluvoxamine: Schizoid personality disorder
One-Sentence Summary
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) marketed in Canada. The TxGNN model predicts it may be effective for schizoid personality disorder, but this is a model prediction only: no clinical trials and 1 publication (an observational study, not a treatment trial) are linked to it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Schizoid personality disorder |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 6 of 6) |
| Number of DINs | 6 (marketed: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Fluvoxamine belongs to the SSRI class, which acts by blocking serotonin reuptake. Serotonergic modulation might plausibly influence some personality traits such as social withdrawal and emotional restriction.
However, this is a hypothesis only. The one linked paper (PMID 10929788) studied personality disorders and traits in people with body dysmorphic disorder. Some of its participants took part in a fluvoxamine treatment study, but the paper did not test fluvoxamine as a treatment for schizoid personality disorder.
Several other personality disorders received identical scores (schizotypal, histrionic, paranoid). This suggests the score reflects a shared pattern in the model rather than disorder-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10929788 | 2000 | Cohort | Comprehensive Psychiatry | Assessed personality disorders and traits in 148 people with body dysmorphic disorder, 26 of whom were in a fluvoxamine treatment study. It describes personality features and does not test treatment of schizoid personality disorder. |
Canada Market Information
| DIN | Product Name | Status |
|---|---|---|
| 01919369 | LUVOX | Valid |
| 01919342 | LUVOX | Valid |
| 02255537 | TEVA-FLUVOXAMINE | Valid |
| 02231330 | APO-FLUVOXAMINE | Valid |
| 02255529 | TEVA-FLUVOXAMINE | Valid |
All six single-ingredient licences in the data are valid; the five above are the main ones shown.
Safety Considerations
- Drug Interactions: 100 interactions were found in the interaction databases. Major-level examples include alosetron, bupropion, diethylpropion and dolasetron. Moderate-level examples include clarithromycin, aspirin, morphine, aprepitant, pioglitazone and several corticosteroids (hydrocortisone, dexamethasone, budesonide, betamethasone, triamcinolone). Co-medication screening would be essential.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. No trial or published study has tested fluvoxamine in schizoid personality disorder, so the evidence level is L5.
To proceed, the following is needed:
- Direct clinical evidence (controlled or open-label studies) of fluvoxamine in schizoid personality disorder
- Mechanism-of-action data linking serotonergic modulation to the core features of this disorder
- Package insert warnings and contraindications from Health Canada
- A co-medication screening plan, given the large number of drug interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.